Develops instruments, OEM modules and assays for molecular pathogen detection. It claims its technology as a new approach to PCR along with cooling and heating rates at different orders and enables physicians and hospitals to diagnose bacterial diseases. Its first product Pharos400 features laser-based PCR technology is for thermal cycling and fluorescence-free real-time readout of results. The company was founded in 2010 and headquartered in Planegg, Germany. It has raised $20.2M in series c funding, with backing from OCCIDENT, GreyBird Ventures, UVC Partners, Mey Capital Matrix, and others. The company operates in the High Tech - Nanotechnology, Life Sciences - Infectious Diseases, Sustainability Tech - Infectious Diseases space. Its offerings span Infectious Diseases - In Vitro Diagnostic Tests - Bacterial and Genomics - Enabling Technologies - Instrument Systems.
GNA Biosolutions
Series CDevelops instruments, OEM modules and assays for molecular pathogen detection. It claims its technology as a new approach to PCR along with cooling and heating rates at different orders and enables physicians and hospitals to diagnose bacterial diseases. Its first product Pharos400 features laser-based PCR technology is for thermal cycling and fluorescence-free real-time readout of results. The company was founded…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Diagnostic > Point of Care,
Infectious Diseases > In Vitro Diagnostic Tests > Bacterial,
Genomics > Enabling Technologies > Instrument Systems > Nucleic Acid Analysis > Imaging,
Life Sciences Platforms and Tools > Instruments > Genomics > Nucleic Acid Sequencing
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Backed by funds in our directory
🗂️ Explore High Tech investors — funds that write checks in this sector.